ReviewTranslational lung cancer research2023
Early-stage anaplastic lymphoma kinase (
Review in Translational lung cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies.Technology in cancer research & treatmentPooled it
- Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.Nature reviews. Clinical oncology · 2026Review
- Prevalence and clinical outcomes of anaplastic lymphoma kinase rearrangements in surgically resected adenocarcinoma lung cancer: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Neoadjuvant ALK tyrosine kinase inhibitor in patients with resectable locally advanced non-small cell lung cancer harboringTranslational lung cancer research · 2026Article
- Actionable driver gene alterations in early-stage non-small cell lung cancer: a review.Therapeutic advances in medical oncology · 2026Review
- Surgical consensus for screening, diagnosis, staging, multimodal management and surveillance of early-stage resectable non-small cell lung cancer (NSCLC) in Malaysia.Translational lung cancer research · 2025Review
- Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada.PharmacoEconomics · 2025Article
- Predictors of occult lymph node metastasis in clinical T1 lung adenocarcinoma: a retrospective dual-center study.BMC pulmonary medicine · 2025Article
- Pathological Complete Response in Locally AdvancedSurgical case reports · 2025Article
- Article
- Ensartinib as a neoadjuvant therapy for stage IIIA non-small cell lung cancer patients with EML4-ALK fusion: a case report and literature review.Frontiers in oncology · 2025Article
- Successful long-term outcome of neoadjuvant sequential targeted therapy and chemotherapy for stage III non-small cell lung carcinoma: 10 case series.Translational lung cancer research · 2024Article
- What do we know about the role of neoadjuvant targeted therapy in early-stageTranslational lung cancer research · 2024Review
- Current opportunities and challenges in ALK-positive lung cancer.Translational lung cancer research · 2024Article
- Prognostic factors of resectable anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients: a retrospective analysis based on a single center.Translational lung cancer research · 2024Article
- Recent Advances in Adjuvant Therapy for Non-Small-Cell Lung Cancer.Tuberculosis and respiratory diseases · 2024Article
- Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (Translational lung cancer research · 2023Article
- Clinical characteristics and progression of pre-/minimally invasive lung adenocarcinoma harboringTranslational lung cancer research · 2023Article
- A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Background and Objective: While anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are standard of care treatment for metastatic Methods: We identified the references for this narrative review through a literature search of papers about early stage Key Content and Findings: The incidence of oncogenic Conclusions: Attempts at large, randomized trials to evaluate the benefit of ALK TKIs in the adjuvant and neoadjuvant has been hampered by slow recruitment given the rarity of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.